Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01243983 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis
A Phase 3 study, sponsored by Lux Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 155
- Enrollment target
NCT01243983 is a Phase 3 study that has completed, run by Lux Biosciences. The registered enrollment target is 155 participants.
The verdict
NCT01243983, a Phase 3 study, has completed, sponsored by Lux Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 155 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and efficacy of voclosporin as therapy in subjects with active noninfectious uveitis involving the intermediate and/or posterior segments of the eye (i.e., anterior + intermediate-, intermediate-, posterior- or pan-uveitis).
Interventions
- DRUG LX211
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2011-02 |
| Est. Completion | 2012-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01243983
The ClinicalTrials.gov registry entry for NCT01243983 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lux Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LX211 is the first listed.
NCT01243983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01243983 about?
NCT01243983 is a clinical study titled "Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis". The primary objective of this study is to assess the safety and efficacy of voclosporin as therapy in subjects with active noninfectious uveitis involving the intermediate and/or posterior segments of the eye (i.e., anterior + intermediate-, intermediate-, posterior- or pan-uveitis).
What is the current status of trial NCT01243983?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 155 participants. The study started on 2011-02. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01243983?
The interventions under investigation include: LX211 (DRUG).
Who is sponsoring clinical trial NCT01243983?
This trial is sponsored by Lux Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.